{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:05:40Z","timestamp":1791889540445,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1007\/s11864-004-0040-4","type":"journal-article","created":{"date-parts":[[2007,6,28]],"date-time":"2007-06-28T08:42:06Z","timestamp":1183020126000},"page":"519-526","source":"Crossref","is-referenced-by-count":11,"title":["Targeted molecular therapy for malignant gliomas"],"prefix":"10.1007","volume":"5","author":[{"given":"L. Burt","family":"Nabors","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"40_CR1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1212\/WNL.35.2.219","volume":"35","author":"AE Walker","year":"1985","unstructured":"Walker AE, Robins M, Weinfeld FD: Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 1985, 35:219\u2013226.","journal-title":"Neurology"},{"key":"40_CR2","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1002\/1097-0142(19870501)59:9<1617::AID-CNCR2820590916>3.0.CO;2-X","volume":"59","author":"PC Burger","year":"1987","unstructured":"Burger PC, Green SB: Patient age, histological features, and length of survival in patients with glioblastoma multiforme. Cancer, 1987, 59:1617\u20131625.","journal-title":"Cancer"},{"key":"40_CR3","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1101\/gad.891601","volume":"15","author":"EA Maher","year":"2001","unstructured":"Maher EA, Furnari FB, Bachoo RM, et al.: Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001, 15:1311\u20131333. This is an excellent review of the cellular origins of glioma and the molecular pathways important for the normal and neoplastic development of glial cells.","journal-title":"Genes Dev"},{"key":"40_CR4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1750-3639.1996.tb00848.x","volume":"6","author":"K Watanabe","year":"1996","unstructured":"Watanabe K, Tachibana O, Sata K, et al.: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996, 6:217\u2013223.","journal-title":"Brain Pathol"},{"key":"40_CR5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3171\/jns.1990.72.6.0941","volume":"72","author":"L Recht","year":"1990","unstructured":"Recht L, Torres CO, Smith TW, et al.: Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. Neurosurg 1990, 72:941\u2013945.","journal-title":"Neurosurg"},{"key":"40_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1126\/science.3498987","volume":"238","author":"L Greenfield","year":"1987","unstructured":"Greenfield L, Johnson VG, Youle RJ: Mutations in diphtheria toxin separate binding from entry and amplified immunotoxin selectivity. Science 1987, 238:536\u2013539.","journal-title":"Science"},{"key":"40_CR7","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/nm1297-1362","volume":"3","author":"D Laske","year":"1997","unstructured":"Laske D, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997, 3:1362\u20131368.","journal-title":"Nat Med"},{"key":"40_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1023\/A:1026246500788","volume":"65","author":"M Weaver","year":"2003","unstructured":"Weaver M, Laske D: Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107 for therapy of malignant glioma. J Neurooncol 2003, 65:3\u201313. This manuscript reviews the preclinical and early phase clinical development of the transferrin receptor ligand-targeted toxin with particular emphasis on the specific binding and in vivo specificity followed by results of the phase I and II trials.","journal-title":"J Neurooncol"},{"key":"40_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/313144a0","volume":"313","author":"TA Libermann","year":"1985","unstructured":"Libermann TA, Nusbaum HR, Razon N, et al.: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature 1985, 313:144\u2013147.","journal-title":"Nature"},{"key":"40_CR10","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1002\/cncr.10372","volume":"94","author":"RS Herbst","year":"2001","unstructured":"Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. Cancer 2001, 94:1593\u20131611.","journal-title":"Cancer"},{"key":"40_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/02724570152057634","volume":"20","author":"T Crombet","year":"2001","unstructured":"Crombet T, Osorio M, Cruz T, et al.: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma 2001, 20:131\u2013136.","journal-title":"Hybridoma"},{"key":"40_CR12","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/0959-8049(95)00592-7","volume":"32A","author":"G Stragliotto","year":"1996","unstructured":"Stragliotto G, Vega F, Stasiecki P, et al.: Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55900) in patients with recurrent malignant glioma. Eur J Cancer 1996, 32A:636\u2013640.","journal-title":"Eur J Cancer"},{"key":"40_CR13","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/1097-0215(20001215)88:6<962::AID-IJC20>3.0.CO;2-U","volume":"88","author":"CT Kuan","year":"2000","unstructured":"Kuan CT, Wikstrand CJ, Archer G, et al.: Increased binding affinity enhances targeting of glioma xenografts by egfrvIII-specific scFv. Int J Cancer 2000, 88:962\u2013969.","journal-title":"Int J Cancer"},{"key":"40_CR14","first-page":"1008","volume":"54","author":"PC Phillips","year":"1994","unstructured":"Phillips PC: Transforming growth factor alpha Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res, 1994. 54:1008\u20131015.","journal-title":"Cancer Res"},{"key":"40_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1023\/A:1026290315809","volume":"65","author":"J Sampson","year":"2003","unstructured":"Sampson J, Akabani G, Archer GE, et al.: Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF-a) and a mutated form of Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Neurooncol 2003, 65:27\u201335.","journal-title":"Neurooncol"},{"key":"40_CR16","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ijc.2910580421","volume":"58","author":"R Puri","year":"1994","unstructured":"Puri R: Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the cytotoxic effects of IL-4 Pseudomonas exotoxin chimeric protein. Int J Cancer 1994. 58:574\u2013581.","journal-title":"Int J Cancer"},{"key":"40_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1024901501173","volume":"64","author":"F Weber","year":"2003","unstructured":"Weber F, Asher A, Bucholz R, et al.: Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 2003, 64:125\u2013137.","journal-title":"J Neurooncol"},{"key":"40_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/362248a0","volume":"362","author":"A Minty","year":"1993","unstructured":"Minty A, Chalon P, Derocq JM, et al.: Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993, 362:248.","journal-title":"Nature"},{"key":"40_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1182>3.0.CO;2-N","volume":"92","author":"S Husain","year":"2001","unstructured":"Husain S, Joshi BH, Puri R: Interleukin-13 receptor as a unique target for antiglioblastoma therapy. Int J Cancer 2001, 92:168\u2013175. This preclinical study provided the scientific rationale for the development of a glioma targeted therapy utilizing the IL-13 molecule.","journal-title":"Int J Cancer"},{"key":"40_CR20","doi-asserted-by":"publisher","first-page":"16775","DOI":"10.1074\/jbc.270.15.8797","volume":"270","author":"W Debinski","year":"1995","unstructured":"Debinski W, Obiri NI, Pastan I, Puri RK: A novel chimeric protein composed of interleukin-13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing the receptors for interleukin 13 and interleukin 4. J Biol Chem 1995, 270:16775\u201316780.","journal-title":"J Biol Chem"},{"key":"40_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1023\/A:1026242432647","volume":"65","author":"S Husain","year":"2003","unstructured":"Husain S, Puri R: Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 2003, 65:37\u201348.","journal-title":"J Neurooncol"},{"issue":"4","key":"40_CR22","first-page":"357","volume":"5","author":"J Weingart","year":"2003","unstructured":"Weingart J: Intratumoral convection-enchanced delivery of IL13-PE38QQR cytotoxin for recurrent malignant glioma without planned resection: a phase I\/II study. J Neurooncol 2003, 5(4):357.","journal-title":"J Neurooncol"},{"issue":"4","key":"40_CR23","first-page":"351","volume":"5","author":"S Kunwar","year":"2003","unstructured":"Kunwar, S: Peritumoral convection-enhanced delivery of IL13-PE38QQR in patients with recurrent malignant glioma -phase I interim results. J Neuroonco, 2003, 5(4): 351.","journal-title":"J Neuroonco"},{"key":"40_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/glia.10083","volume":"39","author":"SA Lyons","year":"2002","unstructured":"Lyons SA, O\u2019Neal J, Sontheimer H: Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 2002, 39:162\u2013173. This study along with the one by Deshane et al. [25] characterize the unique chlorotoxin receptor present on transformed glial cells and identifies a role in glioma invasion and migration.","journal-title":"Glia"},{"key":"40_CR25","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1074\/jbc.M205662200","volume":"278","author":"J Deshane","year":"2003","unstructured":"Deshane J, Garner CC, Sontheimer H: Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem 2003, 278:4135\u20134144.","journal-title":"J Biol Chem"},{"key":"40_CR26","first-page":"4871","volume":"58","author":"L Soroceanu","year":"1998","unstructured":"Soroceanu L, Gillespie Y, Khazaeli MB, Sontheimer H, et al.: Use of chlorotoxin for targeting of primary brain tumors. Cancer Res 1998, 58:4871\u20134879.","journal-title":"Cancer Res"},{"key":"40_CR27","first-page":"340","volume":"5","author":"AN Mamelak","year":"2003","unstructured":"Mamelak AN: A phase I\/II trial of intracavitary 131ITM-601 in adult patients with recurrent high-grade glioma. J Neurooncol 2003, 5:340.","journal-title":"J Neurooncol"},{"key":"40_CR28","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/jnci\/93.14.1062","volume":"93","author":"AA Adjei","year":"2001","unstructured":"Adjei AA, Blocking oncogenic ras signaling for cancer therapy. J Natl Cancer Inst 2001, 93:1062\u20131074.","journal-title":"J Natl Cancer Inst"},{"key":"40_CR29","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1038\/sj.onc.1201455","volume":"15","author":"A Guha","year":"1997","unstructured":"Guha A, Feldkamp MM, Lau N, et al.: Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 1997, 15:2755\u20132765.","journal-title":"Oncogene"},{"key":"40_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/glia.440150307","volume":"15","author":"B Westermark","year":"1995","unstructured":"Westermark B, Heldin CH, Nister M: Platelet-derived growth factor in human glioma. Glia 1995, 15:257\u2013263.","journal-title":"Glia"},{"key":"40_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0092-8674(91)90222-K","volume":"64","author":"HJ Yeh","year":"1991","unstructured":"Yeh HJ, Ruit KG, Wang YX, et al.:Platelet-derived growth factor (PDGF) A-chain gene is expressed by mammalian neurons during development and in maturity. Cell 1991, 64:209\u2013216.","journal-title":"Cell"},{"key":"40_CR32","first-page":"2987","volume":"52","author":"A von Deimling","year":"1992","unstructured":"von Deimling A, Eibl RH, Ohgaki H, et al.: p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992, 52:2987\u20132990.","journal-title":"Cancer Res"},{"key":"40_CR33","doi-asserted-by":"publisher","first-page":"6899","DOI":"10.1073\/pnas.84.19.6899","volume":"84","author":"AJ Wong","year":"1987","unstructured":"Wong AJ, Bigner SH, Bigner DD, et al.: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987, 84:6899\u20136903.","journal-title":"Proc Natl Acad Sci USA"},{"key":"40_CR34","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1073\/pnas.89.10.4309","volume":"89","author":"AJ Ekstrand","year":"1992","unstructured":"Ekstrand AJ, Sugawa N, James CD, Collins VP, et al.: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and\/or C-terminal tails. Proc Natl Acad Sci USA 1992, 89:4309\u20134313.","journal-title":"Proc Natl Acad Sci USA"},{"key":"40_CR35","first-page":"356","volume":"5","author":"JN Rich","year":"2003","unstructured":"Rich JN: Phase I\/II trial of the epidermal growth factor receptor small molecule inhibitor ZD1839 (gefitinib) in patients with first relapse glioblastoma. J Neurooncol 2003, 5:356.","journal-title":"J Neurooncol"},{"key":"40_CR36","first-page":"356","volume":"5","author":"MA Vogelbaum","year":"2003","unstructured":"Vogelbaum MA: Initial experience with the EGFR tyrosine kinase inhibitor tarceva (OSI-774) for singleagent therapy of recurrent\/progressive glioblastoma multiforme. J Neurooncol 2003, 5:356.","journal-title":"J Neurooncol"},{"key":"40_CR37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/0092-8674(93)90146-H","volume":"73","author":"L Buday","year":"1993","unstructured":"Buday L, Downward J: Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adaptor protein, and Sos nucleotide exchange factor. Cell 1993, 73:611\u2013620.","journal-title":"Cell"},{"key":"40_CR38","first-page":"643","volume":"366","author":"JL Goldstein","year":"1990","unstructured":"Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990, 366:643\u2013654.","journal-title":"Nature"},{"key":"40_CR39","first-page":"349","volume":"5","author":"TF Cloughesy","year":"2003","unstructured":"Cloughesy TF: Two phase II trials of R115777 (Zarnestra) in patients with recurrent glioblastoma multiforme (GBM): a comparison of patients on enzyme-inducing anti-epileptic drugs and not on EIAED at maximum tolerated dose respectively. J Neurooncol 2003, 5:349.","journal-title":"J Neurooncol"},{"key":"40_CR40","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/10533","volume":"5","author":"JS Sebolt-Leopold","year":"1999","unstructured":"Sebolt-Leopold JS: Blockade of the mitogen activated protein (MAP) kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999, 5:810\u2013816.","journal-title":"Nat Med"},{"key":"40_CR41","doi-asserted-by":"publisher","first-page":"12479","DOI":"10.1073\/pnas.94.23.12479","volume":"94","author":"FB Furnari","year":"1997","unstructured":"Furnari FB, Lin H, Huang HS, Cavenee WK: Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA 1997, 94:12479\u201312484.","journal-title":"Proc Natl Acad Sci USA"},{"key":"40_CR42","first-page":"4183","volume":"57","author":"SI Wang","year":"1997","unstructured":"Wang SI: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997, 57:4183\u20134186.","journal-title":"Cancer Res"},{"key":"40_CR43","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S0092-8674(00)80108-7","volume":"86","author":"D Hanahan","year":"1996","unstructured":"Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:352\u2013364.","journal-title":"Cell"},{"issue":"Suppl 1","key":"40_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1634\/theoncologist.5-suppl_1-11","volume":"5","author":"LM Ellis","year":"2000","unstructured":"Ellis LM, Takahashi Y, Liu W, Shaheen RM: Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000, 5(Suppl 1):11\u201315.","journal-title":"Oncologist"},{"key":"40_CR45","first-page":"355","volume":"5","author":"DA Reardon","year":"2003","unstructured":"Reardon DA: Preliminary phase I trial results: PTK787\/ ZK222584 (PTK\/ZK) an oral VEGF tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme. J Neurooncol 2003, 5:355.","journal-title":"J Neurooncol"},{"key":"40_CR46","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.20.5.1383","volume":"20","author":"M Groves","year":"2002","unstructured":"Groves M, Puduvalli VK, Hess KR, et al.: Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor Marimastat in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002, 20:1383\u20131388.","journal-title":"J Clin Oncol"},{"key":"40_CR47","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1073\/pnas.84.18.6471","volume":"84","author":"D Cheresh","year":"1987","unstructured":"Cheresh D: Human endothelial cells synthesize and express an Arg-Gly-Asp directed adhesion receptor involved in attchement to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA 1987, 84:6471\u20136475.","journal-title":"Proc Natl Acad Sci USA"},{"key":"40_CR48","first-page":"373","volume":"4","author":"LB Nabors","year":"2002","unstructured":"Nabors LB, Rosenfeld R, Mikkelsen T: A phase I trial of EMD 121974 for treatment of patients with recurrent malignant glioma. J Neurooncol 2002, 4:373.","journal-title":"J Neurooncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-004-0040-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-004-0040-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-004-0040-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-004-0040-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T13:15:38Z","timestamp":1652620538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-004-0040-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["40"],"URL":"https:\/\/doi.org\/10.1007\/s11864-004-0040-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}